Viracta Therapeutics’ (VIRX) Neutral Rating Reaffirmed at Rodman & Renshaw

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “neutral” rating reiterated by stock analysts at Rodman & Renshaw in a note issued to investors on Friday,Benzinga reports. They currently have a $0.25 price target on the stock, down from their prior price target of $3.50. Rodman & Renshaw’s target price points to a potential upside of 5.49% from the company’s previous close.

Separately, Royal Bank of Canada dropped their price objective on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Viracta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $4.05.

Viracta Therapeutics Price Performance

Shares of Viracta Therapeutics stock opened at $0.24 on Friday. Viracta Therapeutics has a 1 year low of $0.13 and a 1 year high of $1.31. The firm has a market cap of $9.42 million, a PE ratio of -0.22 and a beta of 0.67. The company has a 50 day simple moving average of $0.19 and a two-hundred day simple moving average of $0.32.

Institutional Investors Weigh In On Viracta Therapeutics

A hedge fund recently bought a new stake in Viracta Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned about 1.27% of Viracta Therapeutics as of its most recent SEC filing. 31.37% of the stock is currently owned by institutional investors.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.